Precigen Announces Full FDA Approval Of Papzimeos
ReutersAug 15, 2025 11:23 AM
Aug 15 (Reuters) - Precigen Inc PGEN.O:
PRECIGEN ANNOUNCES FULL FDA APPROVAL OF PAPZIMEOS (ZOPAPOGENE IMADENOVEC-DRBA), THE FIRST AND ONLY APPROVED THERAPY FOR THE TREATMENT OF ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Micron Technology Q4 FY2025 Earnings Preview: Leveraging DRAM Strength and Accelerating HBM Growth
TradingKey - Micron Technology, Inc. (NASDAQ: MU) will report Q4 FY2025 results after the market close on Tuesday, September 23, 2025, with the webcasted conference call scheduled for 4:30 PM EDT. As a leading global supplier of memory chips, including DRAM, NAND flash, and advanced memory like...TradingKey
6 hours ago
Fed Rate Cuts: Will the Russell 2000 Outperform the S&P 500?
TradingKey - On 17 September, the Federal Reserve cut interest rates by 25 basis points, marking the official restart of the rate-cutting cycle. In theory, small-cap stocks, compared to large-cap stocks, benefit more from Fed rate cuts. This is because they are more reliant on external financing...TradingKey
22 hours ago
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
Fri, Sep 12
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.TradingKey
Thu, Aug 7
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
Tradingkey
